Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Don’t Miss

28 Nov 2022

News You Might Have Missed: Nov 28th 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Press Releases

21 Nov 2022

Nushama & Awakn Sign Agreement for Alcohol Disorder Treatment in NYC

NUSHAMA AND AWAKN BRING REVOLUTIONARY ALCOHOL USE DISORDER TREATMENT TO NEW YORK — EFFICACY AT A FRACTION OF THE USUAL COST...

By Microdose NewsDesk

Don’t Miss

21 Nov 2022

News You Might Have Missed: Nov 21st, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

17 Nov 2022

MAPS Completes Second Phase 3 MDMA Trial

MAPS Completes Second Phase 3 "MAPP2" Trial of MDMA-Assisted Therapy for Treatment of PTSD...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

15 Nov 2022

Clearmind Medicine Uplists to the NASDAQ

In surprising news, psychedelic upstart Clearmind Medicine has uplisted to the NASDAQ....

By Microdose NewsDesk

Don’t Miss

14 Nov 2022

News You Might Have Missed: Nov 14th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

11 Nov 2022

Atai Reports Q3 Financials and Business Update

atai Life Sciences has the biggest product portfolio in the psychedelics medicine space, with over a dozen programs running under a wide range of subsidiary companies....

By Microdose NewsDesk

Industry

3 Nov 2022

PharmaTher Enters into Agreement to Commercialize Ketamine for Rett Syndrome

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome...

By Microdose NewsDesk

Industry

31 Oct 2022

Small Pharma Receives Approval for Phase I DMT Clinical Trial

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.